Merck & Co launches Saflutan in the UK and Spain
This article was originally published in Scrip
Executive Summary
Merck & Co has launched the prostaglandin F2-alpha analogue Saflutan (tafluprost, licensed from Santen) in the UK and Spain, for the reduction of intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension.